Pending patent expiration, Alkermes-Biogen MS therapy nears final FDA approval

Alkermes disclosed that FDA has granted tentative approval of Vumerity diroximel fumarate (BIIB098) to treat multiple sclerosis, signaling that full approval could come following the

Read the full 258 word article

User Sign In